Statute Details
- Title: Health Products Act 2007 (HPA2007)
- Full Title: An Act to regulate the manufacture, import, supply, presentation and advertisement of health products and of active ingredients used in the manufacture of health products and provide for matters connected therewith.
- Type: Act of Parliament
- Status (as provided): Current version as at 26 Mar 2026
- Commencement: Not specified in the extract (see section 1 in the Act)
- Key Purpose: Establishes a regulatory framework for health products (including active ingredients), covering manufacturing, importation, supply, presentation, advertisement, licensing, registration, and enforcement
- Notable Early Scope Provision: Section 4 (Act applies only to health products specified in the First Schedule)
- Veterinary Carve-out: Section 5 (Act does not apply to supply/use for veterinary purposes, subject to Part 14)
- Enforcement & Evidence: Parts 10–11 (powers, presumptions, analyst evidence)
- Offences & Penalties: Part 12 (including corporate liability and forfeiture)
- Veterinary Regulation: Part 14 (sections 73–75)
What Is This Legislation About?
The Health Products Act 2007 (“HPA”) is Singapore’s core statute governing “health products” and certain “active ingredients” used to manufacture them. In practical terms, it is designed to ensure that products marketed for health-related purposes are properly controlled across the supply chain—manufacture, import, wholesaling, presentation, and advertising. The Act aims to protect consumers by reducing risks associated with unsafe, ineffective, adulterated, counterfeit, or misleading health products.
At a high level, the HPA creates a system of licensing and registration. Businesses that manufacture or import health products must comply with regulatory requirements, and health products themselves must be registered (subject to categories and descriptions in the First Schedule). The Act also regulates how health products may be advertised, including prohibitions on false or misleading claims and additional requirements for advertisements.
Finally, the Act provides enforcement mechanisms and evidentiary tools. It empowers enforcement officers, addresses document handling, and includes presumptions that assist prosecution. For practitioners, the HPA is therefore not only a “compliance” statute but also a “litigation-ready” framework: it sets out how regulators can investigate and how courts can infer key facts in enforcement proceedings.
What Are the Key Provisions?
Scope and interpretation (Parts 1 and First Schedule). The Act’s reach is not universal to all consumer goods. Section 4 provides that the HPA applies only to health products specified in the First Schedule. This is crucial for classification disputes: if a product is not within the First Schedule categories/descriptions, the Act may not apply (subject to how “health product” is interpreted in section 2 and any relevant regulatory definitions). Section 3 sets out the purposes of the Act, which guide interpretation and enforcement discretion.
Veterinary carve-out and Part 14. Section 5 states that the Act does not apply to supply or use of health products and active ingredients for veterinary purposes. However, the Act does not leave veterinary regulation unaddressed: Part 14 (sections 73–75) regulates supply and use for veterinary purposes through regulations and provides enforcement powers for those regulations. Practitioners should therefore treat veterinary use as a distinct compliance track, rather than assuming the HPA is entirely inapplicable.
Manufacture and import controls (Part 3). Sections 12 and 13 address manufacture and import of health products. While the extract lists these provisions at a high level, the structure indicates that the Act imposes requirements on who may manufacture/import and under what conditions. These provisions typically operate alongside licensing and registration obligations in later Parts. For counsel advising regulated businesses, the key practical question is sequencing: registration of the product (Part 7) and licensing/authorisation of the business (Part 6) will usually be prerequisites to lawful dealings.
Supply restrictions and quality/identity prohibitions (Part 4). Part 4 is central to market conduct. Section 14 deals with wholesaling of health products, while section 15 prohibits supply of unregistered health products. Section 16 prohibits supply of health products that are adulterated, counterfeits, etc. Section 17 requires supply to be carried out in accordance with prescribed requirements, and section 18 addresses “presentation” of health products—an area that often overlaps with packaging, labelling, and how information is conveyed to consumers.
Advertisement regulation (Part 5). The HPA regulates not only what products are sold, but also how they are marketed. Section 19 governs advertisement of health products. Section 20 prohibits false or misleading advertisement, and section 21 adds further requirements for advertisements (for example, likely including prescribed content, approvals, or substantiation requirements). Section 22 provides defences, and section 23 allows corrective measures in relation to contravening advertisements. Practitioners should note that advertisement enforcement can be fast-moving and evidence-heavy: regulators may rely on presumptions about identity and purpose (Part 11) and on analyst evidence (section 57) depending on the alleged product characteristics.
Licensing framework (Part 6). Part 6 provides for issue and renewal of licences (section 24), variation of licence conditions (section 25), and a register of licensees (section 26). It also provides for suspension and revocation of licences and cancellation of approval (section 27), with an appeal mechanism (section 28). For regulated entities, this part is often the compliance “backbone”: even where a product is registered, the business may still be prohibited from operating without the appropriate licence or subject to conditions.
Registration of health products (Part 7). Part 7 is the heart of product-level control. Section 29 provides that health products must be registered according to categories in the First Schedule. Section 30 sets out registration requirements, section 31 addresses duration, and section 32 provides conditions of registration. Section 33 requires evaluation of health products—indicating that registration is not automatic and likely depends on quality, safety, and efficacy assessments. Section 34 establishes a register of health products.
Sections 35 and 36 address re-categorisation or re-classification: registrants can apply for changes, and the Authority may re-categorise/re-classify in the absence of application. Section 37 provides for suspension and cancellation of registration, and section 38 provides for appeal. Practically, these provisions matter for lifecycle management: product reformulations, new evidence, or changes in regulatory classification can trigger re-evaluation and compliance adjustments.
Duties of manufacturers/importers (Part 8). Part 8 imposes ongoing obligations beyond initial licensing/registration. Section 40 requires keeping of records. Section 41 requires furnishing of information or documents regarding a health product. Section 42 requires reporting of defects and adverse effects to the Authority. Section 43 requires verification of quality, safety and efficacy. Section 44 requires notification concerning recall of a health product. Section 45 adds additional duties under regulations. For practitioners, these duties are often the basis for enforcement even where the product was previously registered—because adverse events, quality failures, or incomplete documentation can constitute contraventions.
Active ingredients regulation (Parts 9 and 10–11). Part 9 regulates dealings in active ingredients used in manufacture. Section 46 identifies active ingredients to which Part 9 applies, and section 47 regulates manufacture, import, supply, etc. This is important for supply chain counsel: a business may be implicated not only for the finished product but also for upstream ingredients.
Enforcement powers and evidentiary presumptions (Parts 10 and 11). Section 48 addresses non-compliant health products and active ingredients. Section 49 provides powers of enforcement, and section 50 deals with unlawful alteration, destruction, etc. of documents. Section 51 prohibits obstructing officers. Part 11 then strengthens enforcement by providing presumptions: for example, section 52 presumes liability of importers and manufacturers; section 53 presumes identity of advertiser; section 54 presumes purpose for which a health product is manufactured/imported/supplied; section 55 presumes similarity in properties between products found and samples taken; section 56 presumes intention to supply based on possession; and section 57 provides for evidence of analyst. These provisions can significantly affect litigation strategy and evidential burdens.
Offences and prosecution (Part 12). Part 12 covers jurisdiction (section 58), offences by bodies corporate (section 59), enhanced penalty for corporations (section 60), liability for offences by agents or employees (section 61), forfeiture (section 62), recovery of fees and expenses incidental to prosecution (section 63), non-disclosure of information (section 64), and composition of offences (section 65). For corporate clients, sections 59–61 are particularly important: they can create direct exposure for companies and for responsible persons depending on how offences are structured.
Miscellaneous provisions (Part 13) and regulations. Part 13 includes protection of confidential information (section 66), service of documents (section 67), form and authentication of notices/orders (section 68), inaccuracies in documents (section 69), exemption (section 70), fees (section 71), and regulation-making powers (section 72). These provisions support the operational functioning of the regulatory regime.
Veterinary purposes (Part 14). Sections 73–75 regulate supply and use for veterinary purposes through regulations and provide enforcement powers and the application of Parts 10–13. This ensures that enforcement tools and offences frameworks can apply appropriately in the veterinary context.
How Is This Legislation Structured?
The HPA is organised into 14 Parts. Part 1 sets out preliminary matters: short title, interpretation, purposes, and scope limitations (including the First Schedule and the veterinary carve-out). Part 2 covers administration, including enforcement officers, analysts, and advisory/appeal advisory committees. Parts 3–4 regulate manufacture, import, wholesaling, supply, and presentation. Part 5 regulates advertisement and provides defences and corrective measures. Part 6 establishes licensing. Part 7 establishes product registration and evaluation, including re-categorisation and appeals. Part 8 imposes ongoing duties on manufacturers/importers, including record-keeping, adverse event reporting, quality verification, and recall notification. Part 9 regulates active ingredients. Parts 10–11 provide enforcement powers and evidentiary presumptions. Part 12 sets out offences and prosecution mechanics. Part 13 contains miscellaneous provisions, including confidentiality and regulations. Part 14 addresses veterinary supply and use, including how enforcement and offence provisions apply.
Who Does This Legislation Apply To?
The HPA applies to persons involved in regulated “health products” and specified “active ingredients” within the meaning of the Act and the First Schedule. This includes manufacturers, importers, wholesalers/suppliers, advertisers, and businesses holding licences or seeking registration. It also affects downstream actors who present or market products, because advertisement and presentation provisions can create liability even where the actor is not the manufacturer.
For veterinary purposes, section 5 indicates that the general scheme does not apply, but Part 14 brings in a parallel regulatory approach through regulations. Accordingly, veterinary product supply chains should assess whether their products and uses fall within the veterinary regulatory track rather than the general consumer health product regime.
Why Is This Legislation Important?
The HPA is significant because it combines product safety/quality objectives with a comprehensive regulatory control system. By requiring registration of health products and licensing/authorisation of regulated activities, it creates a structured pathway for lawful market access. At the same time, it imposes continuing duties—especially record-keeping, adverse event reporting, quality verification, and recall notification—so compliance is not a one-off event.
From an enforcement and litigation perspective, the Act is also important because it includes presumptions and evidentiary provisions that can make prosecutions more effective. Presumptions relating to liability of importers/manufacturers, identity of advertisers, purpose of manufacture/supply, similarity of properties, intention to supply, and analyst evidence can reduce evidential hurdles for regulators and increase the need for defendants to prepare robust rebuttal evidence.
For practitioners advising regulated businesses, the practical impact is clear: compliance must cover the entire lifecycle (manufacture/import, registration status, supply practices, presentation/label claims, advertising content, and post-market surveillance such as adverse event reporting and recalls). Counsel should also consider corporate governance and responsibility mapping, given the provisions on corporate offences and liability for agents or employees.
Related Legislation
- Health Sciences Authority Act 2001
- Birds Act 1965
- Health Products Act 2007 (subsidiary legislation and regulations made under the Act)
Source Documents
This article provides an overview of the Health Products Act 2007 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.